• AAPL 175.43
  • AMZN 120.11
  • BTC-USD 27834.873
  • ETH-USD 1867.0077
  • EURUSD 1.0726
  • TSLA 193.17
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. NVZMY.US

Novozymes AS (NVZMY PINK) stock market data APIs

$50.57 0.1(0.2%) as of May 26, 2023

Novozymes AS Financial Data Overview

50.47
50.57
-
50.71
50.33
45.1335-63.127
13 984 M
26.8431
277 M
17 805 M
2.82
0.0168
0.3988
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NVZMY',
Type: 'Common Stock',
Name: 'Novozymes AS',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000F9KN28',
ISIN: NULL,
CUSIP: NULL,
CIK: '1131345',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Basic Materials',
Industry: 'Specialty Chemicals',
GicSector: NULL,
GicGroup: NULL,
GicIndustry: NULL,
GicSubIndustry: NULL,
HomeCategory: NULL,
IsDelisted: false,
}

Novozymes AS Fundamental Data is available in our Financial Data APIs

  • Net Revenue 17 805 M
  • EBITDA 5 775 M
  • Earnings Per Share 1.88
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Novozymes AS Earnings via APIs

  • Latest Release 2023-04-25
  • EPS/Forecast 2.99

Get Novozymes AS End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Novozymes AS latest news via APIs

AXTA or NVZMY: Which Is the Better Value Stock Right Now?

Investors with an interest in Chemical - Specialty stocks have likely encountered both Axalta Coating Systems (AXTA) and Novozymes A/S (NVZMY). But which of these two stocks presents investors with th...

Novozymes delivers stronger than expected Q1 results

Novozymes A/S After the first quarter of 2023, Novozymes delivers stronger results than expected with 5% organic sales growth. The company confirms the 2023 outlook of 4-7% which is expected to be dr...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com
We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy.